The Zacks Analyst Blog Highlights: Kinder Morgan Energy Partners, Copano Energy, Kinder Morgan, Sunoco Logistics Partners and

   The Zacks Analyst Blog Highlights: Kinder Morgan Energy Partners, Copano
  Energy, Kinder Morgan, Sunoco Logistics Partners and ARIAD Pharmaceuticals

PR Newswire

CHICAGO, Jan. 31, 2013

CHICAGO, Jan. 31, 2013 /PRNewswire/ -- announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Kinder Morgan Energy Partners
L.P. (NYSE:KMP), Copano Energy LLC (Nasdaq:CPNO), Kinder Morgan Inc.
(NYSE:KMI), Sunoco Logistics Partners L.P. (NYSE:SXL) and ARIAD
Pharmaceuticals, Inc. (Nasdaq:ARIA).


Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter:

Here are highlights from Wednesday's Analyst Blog:

Kinder Morgan to Take Over Copano

Kinder Morgan Energy Partners L.P. (NYSE:KMP) has plans to take over Copano
Energy LLC (Nasdaq:CPNO) for about $3.22 billion in stock. This would spread
Kinder Morgan's footprint in Texas, Oklahoma and Wyoming. The purchase price
will reach about $5 billion including debt.

Per the deal, Copano shareholders will get $40.91 per share, which is a 23.5%
premium to Copano's closing price of $33.13 on Jan 29. Shares of Kinder Morgan
- which agreed to pay 0.4563 share for each Copano share - closed at $89.66 on
Tuesday on the New York Stock Exchange.

The boards of directors of both the companies approved this unit for unit
agreement, which is expected to close in the third quarter of 2013. The deal
is yet to pass the customary closing conditions that include regulatory
approval and a vote of the Copano unitholders. With more than 14% stake
Copano's largest shareholder − TPG Capital Management LP − has already given
its green signal to the deal.

A midstream entity with operations mainly in Texas, Oklahoma and Wyoming,
Copano has throughput capacity of 2.7 billion cubic feet per day (Bcf/d), and
over 1 Bcf/d of processing capacity and 315 million cubic feet per day of
treating capacity. It has 9 processing plants and holds shares or operates
about 6,900 miles of pipelines.

This Copano acquisition will facilitate Kinder Morgan to pursue development
activities in the prolific Eagle Ford Shale areas of South Texas and also
allow it to enter the Barnett Shale Combo in north Texas as well as the
Mississippi Lime and Woodford shales in Oklahoma.

Kinder Morgan is one of the largest publicly traded master limited
partnerships (MLPs) and generally serves as a benchmark for the pipeline MLP

Kinder Morgan Inc.

(NYSE: KMI), one of the largest mid-stream energy companies in the U.S., owns
the partnership's general partner interest.

Last year's purchase of El Paso Corp for $38 billion positioned Kinder Morgan
as the largest midstream company in North America. It expanded its portfolio
further with the addition of Tennessee Gas Pipeline (TGP) and a portion of El
Paso Natural Gas (EPNG) with this acquisition. Various agreements and
modifications are lined up in the coming years with these assets, which are
expected to augment the partnership's revenues.

Kinder Morgan retains a Zacks Rank #3 (Hold), implying that it is expected to
perform in line with the broader U.S. equity market over the next one to three

Meanwhile, there are certain other energy pipeline operators like Sunoco
Logistics Partners L.P. (NYSE:SXL) that offer value and is worth buying now.
The partnership sports a Zacks Rank #2 (Buy).

ARIAD Closes Share Offering

ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) recently announced the closure of
its previously announced public offering. ARIAD Pharma priced the public
offering of 15.3 million common shares at $19.60 per share, including 1.18
million shares sold to underwriters to cover the over-allotment options.

ARIAD Pharma plans to use the net proceeds from this offering – approximately
$310 million after deducting underwriting discounts and commissions and
estimated offering costs – to facilitate the sales, marketing, manufacturing
and distribution of its oncology candidate Iclusig (ponatinib) on approval.
The company also intends to use the net proceeds from the offering to develop
its other pipeline candidates.

We believe that investor focus will remain on the approval of Iclusig. The
candidate is under review in the US and EU for treating patients suffering
from resistant or intolerant chronic myeloid leukemia (CML) or
Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). A
decision from the US Food and Drug Administration (FDA) is expected by Mar 27,

In Aug 2012, ARIAD Pharma submitted a Marketing Authorization Application
(MAA) for the candidate for the same indication to the European Medicines
Agency (EMA). ARIAD Pharma had requested accelerated assessment of the MAA for
the candidate, which was granted by the Committee for Medicinal Products for
Human Use (CHMP). ARIAD Pharma expects the candidate to be cleared in the EU
in the third quarter of 2013.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.